Globus Medical, Inc. (NYSE:GMED) Stock Holdings Boosted by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH boosted its position in Globus Medical, Inc. (NYSE:GMED) by 0.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 415,241 shares of the medical device company’s stock after purchasing an additional 1,130 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned about 0.30% of Globus Medical worth $34,345,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. V Square Quantitative Management LLC bought a new stake in shares of Globus Medical during the third quarter valued at approximately $27,000. Quarry LP raised its stake in Globus Medical by 698.4% during the 3rd quarter. Quarry LP now owns 495 shares of the medical device company’s stock valued at $35,000 after acquiring an additional 433 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Globus Medical by 230.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after acquiring an additional 385 shares during the period. UMB Bank n.a. grew its stake in shares of Globus Medical by 60.2% in the fourth quarter. UMB Bank n.a. now owns 548 shares of the medical device company’s stock worth $45,000 after purchasing an additional 206 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Globus Medical by 40.7% during the third quarter. GAMMA Investing LLC now owns 888 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 257 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Globus Medical news, SVP Kelly Huller sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $81.01, for a total transaction of $405,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Keith W. Pfeil sold 14,167 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,667 shares of company stock valued at $6,674,554. Company insiders own 18.54% of the company’s stock.

Globus Medical Stock Up 1.7 %

Shares of Globus Medical stock opened at $92.33 on Wednesday. Globus Medical, Inc. has a 12-month low of $49.33 and a 12-month high of $92.42. The firm has a market capitalization of $12.57 billion, a PE ratio of 137.80, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19. The stock’s fifty day moving average is $84.25 and its 200-day moving average is $76.16.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.18. The company had revenue of $625.71 million during the quarter, compared to analyst estimates of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The business’s quarterly revenue was up 63.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.57 earnings per share. Analysts expect that Globus Medical, Inc. will post 2.98 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on GMED. Wells Fargo & Company upped their price objective on shares of Globus Medical from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Stifel Nicolaus increased their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Bank of America raised Globus Medical from an “underperform” rating to a “neutral” rating and boosted their target price for the stock from $80.00 to $97.00 in a report on Thursday, January 9th. Morgan Stanley upgraded Globus Medical from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $83.00 to $100.00 in a research report on Monday, December 2nd. Finally, Royal Bank of Canada lifted their price target on Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $96.91.

Globus Medical Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.